SG Austria/Austrianova announces the appointment of C. Thomas Paschall to the Board, following the previous closing of the 2025 Financing Round led by Checkmate Capital Group

SG Austria/Austrianova (the SG Austria group of companies comprising of Austrianova Singapore, Austrianova Thailand and Anovade UG) (the "Company") is pleased to announce the appointment of C. Thomas Paschall, CEO and Founder of Checkmate Capital, to the Board of the SG Austria group as of April 4th, 2026. This appointment comes after the previous successful closing of a preferred equity round led by Checkmate Capital Group in 2025.

Thomas brings many years of experience in biotech investments and advisory capability to the Company and had already been assisting the Company before being appointed to the Company's Board. Checkmate Capital is U.S. West-coast based, but has a strong focus on Asia that overlaps well with that of SG Austria/Austrianova. Thomas also has extensive Board experience, being a Board Member or Board Advisor to companies throughout the broader biotechnology, pharmaceutical and medical technology industries.

"We are thrilled to welcome Thomas on Board" said Walter H. Gunzburg, the Chairman of SG Austria/Austrianova's board. "We have already benefited from Tom's insight and experience and we welcome the deepening and intensification of our relationship through his appointment to our Board. The last round of financing, commenced in 2025, has enabled the Company to make critical capital expenditures to advance it's activities and further pursue recent joint ventures and industry partnerships that have significantly contributed to increasing the Company's value as it moves forward through 2026." Brian Salmons, CEO, added "As Austrianova focuses more and more on offering partners manufacturing and upscaling, the commercial acumen of Thomas will enhance our business capabilities."

Austrianova Singapore, 2 International Business Park, The Strategy #09-04, Singapore 609930

Austrianova (the SG Austria Group), is a biotech company with a global footprint and op-erations in Singapore, Thailand, and Germany. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the im-mune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications as well as re-balancing the microbiome due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid.
Austrianova now also offers Pep-in-a-Box encapsulation of enzymes, proteins and supplements to pro-tect them from stomach acid digestion as well as GMP4Cells services that include competitively priced Master Cell Bank and Working Cell Bank production and other production services for cell therapy products (such as stem cell therapies and biologics produced from cells e.g., recombinant proteins, exosomes, etc.).

This release was published on openPR.